CDK6 and lymphoid leukemia: This may be explained by the fact that CDK6 is described as a p53 antagonist during oncogenic stress; CDK6 inhibition enforces the expression of proapoptotic factors which is described during lymphoid leukemia transformation as well as in malignant hematopoietic progenitor cells in a JAK2-V617F model.